A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/MTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
Sponsor: Pfizer
A PHASE1 clinical study on Neoplasm, this trial is completed. The trial is conducted by Pfizer and has accumulated 19 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2021 — Sep 2022 [monthly]
Completed PHASE1
▶ Show 14 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Nov 2019 — Sep 2020 [monthly]
Recruiting PHASE1
-
Jan 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Mar 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .